According to the British Academy of Audiology, hearing loss (HL) is the second most common disability in the UK, affecting ...

MSD has reported that the Phase III KEYNOTE-B96 trial of Keytruda plus paclitaxel, with or without bevacizumab, has met its ...

Nuance Pharma’s Ohtuvayre has met the primary endpoint in a Phase III chronic obstructive pulmonary disease (COPD) study in ...

Pasithea has announced the commencement of a Phase I/Ib open-label trial of PAS-004 for treating adults with ...

Revolution Medicines has dosed the first subject in the Phase III RASolve 301 trial with daraxonrasib (RMC-6236) for NSCLC.

ADC Therapeutics has pulled the drug candidate from development, leaving it with one remaining clinical asset.

BridgeBio Pharma has dosed the first subject in the ACT-EARLY study of acoramidis, a drug intended to prevent transthyretin ...

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.

People with bipolar disorder (BD) who have experienced childhood trauma (CT) will frequently document having more depressive ...

Roche has reported overall survival outcomes from a Phase III trial of Perjeta with Herceptin and chemotherapy in early-stage ...

The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for ...

Johnson & Johnson (J&J) has reported new data from the Phase III ICONIC-TOTAL trial, assessing icotrokinra in treating plaque ...